Abstract - European Medical Journal

Continue

Abstracts

Oncology
2 Mins
12 Nov 2019

The Mutational Signature of Spontaneously Developing Tumours in MLH1-/- Mice - Potential Consequences for Immunotherapeutic Approaches

Mismatch repair-deficient (MMR-D) tumours exemplify the prototypic hypermutator phenotype. Owing to the high mutation rates, many neo-antigens…
Oncology
1 Mins
12 Nov 2019

The 2016-2019 ImmunoTOX Assessment Board Report: Results from a Descriptive Real-Life Study of a Collaborative Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

Although immunotherapy is better tolerated globally than chemotherapy, immune checkpoint inhibitors may be associated with immune-related…
Oncology
2 Mins
12 Nov 2019

Measuring the Cancer Burden in Europe: the European Cancer Information System (ECIS)

Cancer is the second leading cause of mortality in European Union (EU) Member States,1 with more than 1.4 million deaths…
Oncology
1 Mins
12 Nov 2019

Phase I Combination Dose-Finding and Phase II Expansion Cohorts of Lenvatinib with Etoposide and Ifosfamide in Patients Aged 2 to ≤25 Years with Relapsed or Refractory Osteosarcoma

Osteosarcoma is the most common primary bone tumour in adolescents and young adults, with no survival improvement in the last few decades…
Diabetes
1 Mins
5 Nov 2019

Perceptions of Life with Diabetes Revealed through a Solution-Focussed Brief Therapy Exercise via Twitter

The ‘Miracle Question’ (MQ) is a questioning tool used in a solution-focussed approach to care. The goal is to help individuals envision a desired future…
Diabetes
2 Mins
5 Nov 2019

Trends in the Incidence of Prediabetes Among Younger and Older Immigrants in Canada, 2011–2017

The burden of prediabetes appears to be increasing worldwide. According to the International Diabetes Federation (IDF), low and middle-income countries…
Diabetes
2 Mins
5 Nov 2019

Once-Weekly Semaglutide versus Daily Canagliflozin in Type 2 Diabetes Mellitus (SUSTAIN 8): How Do They Compare?

Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter-2 inhibitors (SGLT-2i) are effective and well-tolerated…
Diabetes
2 Mins
5 Nov 2019

SUSTAIN 10: Efficacy and Safety of Semaglutide 1.0 mg Once Weekly versus Liraglutide 1.2 mg Once Daily

Subcutaneous semaglutide once weekly (OW) and subcutaneous liraglutide once daily (OD) are two glucagon-like peptide-1 receptor agonists (GLP-1RA)…